Comment

Pharmacy Guild of Australia President Professor Trent Twomey has welcomed the establishment of a new Masters of Pharmacy qualification.

Amgen has welcomed Health Minister Mark Butler's confirmation that the PBS listing of osteoporosis therapy EVENITY (romosozumab) has been expanded to a first-line setting for people who have had one fracture and are at very high risk of another.

Why should the community be denied broad expertise through implementation group members because of secrecy obligations? The use of secrecy obligations is a cancer in policy processes.

The Albanese Government's Health Technology Assessment Review implementation group faces one early test: Will its members accept the same operating framework that dominated the review's reference group?

Australian nuclear medicine company Telix Pharmaceuticals has expanded its theranostic pipeline with new assets targeting Fibroblast Activation Protein.

GBMA chair Professor Jane Halton AO PSM said economic modelling shows that each biosimilar molecule listed on the PBS could return up to $100 million to the health budget.

Healthcare providers Ramsay Health Care and Bupa Australia have announced a new program to support the development of the next generation of nurses.

Moderna has announced that Dr Felicia Pradera will succeed Dr Craig Rayner as the director of its Regional Research Centre for Respiratory Medicines and Tropical Diseases.

Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra will bring together more than 100 of Australia’s leading industry figures, policy experts, and innovators with the aim of shaping the future of the nation’s biotech and medtech sectors.

Bristol Myers Squibb Australia is hosting the third annual 'Patient and Parliament Summit' in Canberra today and tomorrow.

Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including former industry executive and current PBAC member Michelle Burke.

Moderna Australia has announced that the TGA has authorised its updated COVID-19 vaccine, SPIKEVAX JN.1, targeting the JN.1 variant of SARS-CoV-2 for people aged 12 and over.